In this review:
Cytotoxicity of lenalidomide is enhanced by curcumin
Cereblon as a drug target, outcomes predictor, and drug resistance mediator
Role of IRF4 in myeloma cell survival
Pomalidomide in lenalidomiderelapsed/ refractory myeloma
Long-term safety of continuous lenalidomide in newly-diagnosed myeloma
MicroRNA as a prognostic and therapeutic target
Effect of hypoxia on exosomal microRNAs is an exciting area of research
Lenalidomide with carfilzomib in pre-symptomatic myeloma
To treat or not to treat smouldering MM? (x 2)
Role of a tumour cell maturation hierarchy in drug resistance
Daratumumab – the most promising antibody in late development?
VTd consolidation should be given post-transplant
Addition of bortezomib to thalidomide produces better outcomes
Please login below to download this issue (PDF)